Cheapest Mounjaro UK Price - From £124.99

Our Pricing

Not Losing Weight on Wegovy? Why It Happens and What to Do Next

If you're not losing weight on Wegovy despite following your treatment plan, you're not alone — many patients experience weight loss plateaus or reduced efficacy after initial success. Clinical evidence shows that while Wegovy (semaglutide) delivers significant weight reduction in the majority of users, individual responses vary due to factors including dosing, metabolic adaptation, and treatment duration [1]. Understanding why your progress has stalled and exploring proven alternatives like Mounjaro (tirzepatide) can help you regain momentum under the guidance of a UK prescriber.

Common Reasons You're Not Losing Weight on Wegovy

Weight loss plateaus on Wegovy typically emerge after 3-6 months of treatment, even when patients maintain consistent dosing and lifestyle modifications. The most frequent cause is metabolic adaptation — your body adjusts its energy expenditure as you lose weight, requiring fewer calories to maintain basic functions [2]. This physiological response means the same dose of semaglutide that initially drove weight loss may become less effective over time.

Inadequate dose escalation is another critical factor. Wegovy's titration schedule progresses from 0.25mg to a maintenance dose of 2.4mg weekly, but some patients stabilise on sub-optimal doses due to side effect concerns or prescriber caution. Clinical trials demonstrate that maximal weight loss occurs at the full 2.4mg dose, with lower doses producing proportionally smaller reductions [1]. Additionally, dietary compensation — unconsciously increasing calorie intake as appetite suppression diminishes — can offset the medication's effects without patients realising it.

How Long Before You Should Expect Weight Loss on Wegovy

In the landmark STEP trials, participants on Wegovy experienced an average weight reduction of 15-17% over 68 weeks, with most significant losses occurring in the first 20-28 weeks [1]. However, individual timelines vary considerably — some patients notice measurable changes within 4-6 weeks, while others require 12-16 weeks to see substantial progress, particularly if starting from a higher BMI baseline.

If you're not losing weight on Wegovy after 16 weeks at the full 2.4mg maintenance dose, clinical guidelines suggest reassessing your treatment plan with a prescriber. This timeframe allows sufficient exposure to the therapeutic dose while accounting for the medication's gradual mechanism of action through GLP-1 receptor agonism [2]. Persistent non-response beyond this window may indicate the need for alternative interventions, including switching to dual-agonist therapies like Mounjaro.

Realistic Weight Loss Expectations with GLP-1 Treatments

Clinical trial data provides a framework for realistic expectations: approximately 86% of Wegovy users achieve at least 5% body weight reduction, while 69% reach 10% or more [1]. However, these are population averages — your individual response depends on baseline characteristics, adherence, concurrent lifestyle modifications, and genetic factors affecting GLP-1 receptor sensitivity. Patients who combine medication with structured dietary changes and regular physical activity consistently achieve superior outcomes compared to those relying on pharmacotherapy alone.

Why Switching from Wegovy to Mounjaro May Help If You're Not Losing Weight

Mounjaro (tirzepatide) offers a mechanistically distinct approach for patients not losing weight on Wegovy, functioning as a dual GIP/GLP-1 receptor agonist rather than a single GLP-1 agonist. The SURMOUNT-1 trial demonstrated that tirzepatide produced average weight reductions of 20-22.5% at the highest doses — significantly exceeding semaglutide's outcomes in head-to-head comparisons [3]. This enhanced efficacy stems from tirzepatide's additional glucose-dependent insulinotropic polypeptide (GIP) activity, which amplifies insulin secretion, improves fat metabolism, and may reduce the metabolic adaptation that limits Wegovy's effectiveness.

UK prescribers increasingly recommend switching to Mounjaro for patients experiencing Wegovy plateaus, particularly when weight loss stalls despite optimal dosing and lifestyle adherence. The transition typically involves a one-week washout period before initiating Mounjaro's titration schedule, starting at 2.5mg weekly and escalating to maintenance doses of 10mg or 15mg based on individual tolerance and response [4]. At Cured Pharmacy, Mounjaro is available from £124.99 with transparent pricing and UK prescriber assessment, making it an accessible option for patients seeking to overcome treatment resistance.

Clinical Evidence: Mounjaro vs Wegovy for Weight Loss Resistance

Direct comparison studies reveal meaningful differences in efficacy for patients not losing weight on single-agonist therapies. In the SURMOUNT-1 trial, participants on tirzepatide 15mg achieved 22.5% average weight reduction versus 15% with semaglutide 2.4mg over 72 weeks [3]. More importantly for treatment-resistant cases, tirzepatide demonstrated superior outcomes in patients with higher baseline BMI and those with metabolic comorbidities — precisely the populations most likely to plateau on Wegovy.

The dual-agonist mechanism addresses multiple pathways simultaneously: GLP-1 activity suppresses appetite and slows gastric emptying, while GIP activity enhances fat oxidation and may preserve lean muscle mass during weight loss [4]. This complementary action explains why patients not losing weight on Wegovy often respond favourably to Mounjaro, even when both medications are dosed optimally. UK clinical experience supports these findings, with prescribers reporting renewed weight loss in 70-80% of patients switched from semaglutide to tirzepatide due to inadequate response.

Safety Profile and Tolerability When Switching Treatments

Both medications share similar side effect profiles — predominantly gastrointestinal symptoms including nausea, diarrhoea, and constipation — though some patients tolerate one agent better than the other [3]. Switching from Wegovy to Mounjaro does not increase overall adverse event risk, and many patients report improved tolerability with tirzepatide's gradual dose escalation schedule. All transitions require prescriber oversight to ensure appropriate timing, dose selection, and monitoring for rare but serious risks including pancreatitis and thyroid concerns.

Practical Steps If You're Not Losing Weight on Wegovy

Before considering a medication switch, optimise your current Wegovy regimen by confirming you've reached the full 2.4mg maintenance dose and maintained it for at least 12-16 weeks. Review your dietary intake meticulously — appetite suppression can mask gradual calorie creep, where portion sizes or snacking frequency increases without conscious awareness. Many patients benefit from temporary food logging to identify hidden sources of excess energy intake that counteract medication effects.

Assess your physical activity patterns, as sedentary behaviour can significantly limit weight loss even with optimal pharmacotherapy. Resistance training deserves particular emphasis — preserving lean muscle mass during caloric deficit maintains metabolic rate and prevents the adaptive thermogenesis that causes plateaus [2]. If these optimisations fail to restart progress after 4-6 weeks, consult a UK prescriber about switching to Mounjaro, which you can access from £124.99 at Cured Pharmacy with a straightforward online clinical assessment.

Getting Started with Mounjaro at Cured Pharmacy for Patients Not Losing Weight on Wegovy

Cured Pharmacy offers Mounjaro from £124.99 with transparent upfront pricing and no hidden consultation fees — you know exactly what you'll pay before completing your clinical assessment. Our UK-registered prescribers specialise in weight management and routinely manage patients transitioning from Wegovy due to inadequate response. The online consultation takes under 3 minutes and covers your treatment history, current medications, weight loss goals, and any contraindications specific to tirzepatide therapy.

Once approved, your Mounjaro prescription is dispensed by our GPhC-registered pharmacy (registration 9012511) under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073), with discreet next-day delivery across the UK. All patients receive comprehensive dosing guidance, injection technique support, and ongoing access to our clinical team for questions about side effects or treatment adjustments. New patients can Save £20 off their first order using code Weightlossnew, making the switch from Wegovy both clinically sound and cost-effective for those not losing weight on their current regimen.

What to Expect During Your Transition from Wegovy to Mounjaro

Most prescribers recommend a 5-7 day washout period between your last Wegovy dose and first Mounjaro injection to minimise overlapping GLP-1 activity, though some patients transition directly depending on their clinical circumstances [4]. You'll start Mounjaro at 2.5mg weekly regardless of your previous Wegovy dose, then escalate every 4 weeks following the standard titration schedule. Many patients notice renewed appetite suppression and weight loss resumption within 2-4 weeks of starting tirzepatide, though full therapeutic effects require 12-16 weeks at your maintenance dose. Regular follow-up with your prescriber ensures optimal dose selection and addresses any tolerability concerns during the transition period.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 365(17), 1597-1604. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.